CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 52 enrolled
Drug / intervention
Salmeterol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02232087
NCT02232087Phase 1Completed

Phase I Single Blind, Randomised, Cross-over Pharmacodynamic Dose Response Study in Healthy Volunteers of Two Pressurized Metered Dose Inhalers (pMDIs) That Deliver Salmeterol and Fluticasone Propionate

Kindeva Drug Delivery·interventional·Posted Sep 4, 2014·Updated Jun 15, 2022

In Brief

A Phase 1 clinical trial evaluating Salmeterol and fluticasone propionate for Healthy. Completed, enrolled 52 participants across 1 site.

Detailed Summary

The purpose of this study is to test the body's response to several doses of two different inhalation products in healthy volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 4, 2014
Enrollment StartJul 1, 2014
Primary CompletionOct 1, 2014
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 11.8 years ago

Interventions

Salmeteroldrug

A, D 2 puffs; B, E 6 puffs; C, F 12 puffs

fluticasone propionatedrug

A, D 2 puffs; B, E 6 puffs; C, F 12 puffs